Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccin...(Gregory M. McKee president and chiefexec...),Health

Date:10/8/2008

Gregory M. McKee, president and chief executive officer at Nventa. "While we are advancing Poly-ICR for our internal development and use, we've been extremely pleased with the interest in Poly-ICR that has been shown by outside parties. We are currently working with vaccine developers worldwide to enable their studies with Poly-ICR and we believe this product will evolve into a revenue generating opportunity for Nventa in the near future."

About Poly-ICR:

Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic T-cell and antibody (B-cell) immune responses against that antigen. Cytotoxic T-cells, also referred to as CD8 T-cells, are required to target and eliminate pathogen- infected or cancerous cells. Antibodies, or B-cells, are required to protect against an infection caused by a pathogen. Poly-ICR, therefore, has potential utility in both the therapeutic and prophylactic areas of immunotherapy and vaccine development. This novel and potent immunomodulator works with the immune system to induce dendritic cell maturation, along with a broad range of inflammatory cytokines and chemokines, to facilitate the prevention and treatment of infectious diseases or cancer.

Data generated using Poly-ICR, in combination with a tumor-associated antigen, have demonstrated that the addition of the adjuvant potently increases the antigen-specific CD8 T-cell levels, which correlated with regression of tumors and prevention of tumor growth in mouse models. Poly-ICR is differentiated from other Poly IC compositions by its high stability and potency in human sera, as well as its consistency in physical-chemical properties. Nventa has successfully manufactured research and development lots of Poly-ICR and expects that its current manufacturing process can be used to produce future cGMP material.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatmen
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Nventa Develops Proprietary Vaccine Adjuvant
2. Nventa to Present at Bio 2008 International Convention
3. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
7. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
8. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
9. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
10. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
11. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)